Stephanie O'Halloran-Wilkerson
Psychiatric/Mental Health · Springfield, MONPI 1811630494
Payments from drug & device makers
Across 110 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$437
- Axsome Therapeutics, Inc.$349
- Teva Pharmaceuticals USA, Inc.$259
- Vanda Pharmaceuticals Inc.$216
- E.r. Squibb & Sons, L.L.C.$202
- Johnson & Johnson$196
- plus $753 from 12 others
What the payments were for
- Food & beverage$2,38599%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $437 |
| Axsome Therapeutics, Inc. | 7 | $349 |
| Teva Pharmaceuticals USA, Inc. | 17 | $259 |
| Vanda Pharmaceuticals Inc. | 8 | $216 |
| E.r. Squibb & Sons, L.L.C. | 10 | $202 |
| Johnson & Johnson | 9 | $196 |
| Lundbeck LLC | 9 | $147 |
| Otsuka America Pharmaceutical, Inc. | 6 | $136 |
| Alkermes, Inc. | 7 | $109 |
| Neurocrine Biosciences, Inc. | 5 | $106 |
| GSK | 1 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Merck | 2 | $34 |
| Edwards Lifesciences | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$250
How this compares
$2,412 in reported general payments places this provider in the 70th percentile of 565 psychiatric/mental health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LybalviOlanzapine/Samidorphan Malate | 20 | $34,718 |
| Duloxetine Hcl | 44 | $1,977 |
| Quetiapine Fumarate | 38 | $1,371 |
| Aripiprazole | 26 | $698 |
| Fluvoxamine Maleate | 26 | $515 |
| Paroxetine Hcl | 14 | $358 |
| Buspirone Hcl | 31 | $341 |
| Prazosin Hcl | 26 | $315 |
| Trihexyphenidyl Hcl | 16 | $312 |
| Olanzapine | 12 | $305 |
| Trazodone Hcl | 21 | $255 |
| Cyproheptadine Hcl | 17 | $234 |
| Sertraline Hcl | 17 | $183 |
| Mirtazapine | 18 | $127 |
| Hydroxyzine Hcl | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Lybalvi | $109 | $34,71820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Springfield
- Erin DuvallSpringfield$275K
- Emily WoukSpringfield$90K
- Karin BaughmanSpringfield$16K
- Tedra EstisSpringfield$13K
- Brian SmithSpringfield$10K
- Ashlee RossnerSpringfield$8K
- Holly JulianSpringfield$6K
- Kendra RasmussenSpringfield$6K
- Aldijana SacicSaint Louis$510K
- Laurel OwensLees Summit$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.